The Indian Vaccine Manufacturers Association (IVMA) on Monday announced Bharat Biotech Co-Founder and Executive Chairman Dr. Krishna M Ella will be its new President for a two-year period.A distinguished scientist and successful entrepreneur, .
Krishna Ella New President Of Indian Vaccine Manufacturers Association menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Synopsis
By way of dispatch to private hospitals, the vaccine has reached various cities, including Amritsar, Bangalore, Chennai, Delhi, Ernakulam, Jaipur, Hyderabad, Kanpur, Kolkata, Guwahati, Mysore, Pune, Raipur, Mohali and Vijayawada.
Reuters
Bharat Biotech Co-Founder and Joint MD Suchitra Ella on Tuesday said that Covaxin has reached thirty cities in thirty days despite some employees being off work due to COVID. COVAXIN reaches 30 cities within 30 day. All our employees are committed, working 24x7 thru lockdowns for the country s immunisation - pls send your prayers to their families, some are still quarantined & off work, Ella said in a tweet. By way of dispatch to private hospitals, the vaccine has reached various cities, including Amritsar, Bangalore, Chennai, Delhi, Ernakulam, Jaipur, Hyderabad, Kanpur, Kolkata, Guwahati, Mysore, Pune, Raipur, Mohali and Vijayawada.
Bharat Biotech Co-Founder and Joint MD Suchitra Ella on Tuesday said that Covaxin has reached thirty cities in thirty days despite some employees being off work due to COVID. COVAXIN reaches 30 cities within 30 day. All our employees are committed, working 24x7 thru lockdowns for the country s immunisation - pls send your prayers to their families, some are still quarantined & off work, Ella said in a tweet. By way of dispatch to private hospitals, the vaccine has reached various cities, including Amritsar, Bangalore, Chennai, Delhi, Ernakulam, Jaipur, Hyderabad, Kanpur, Kolkata, Guwahati, Mysore, Pune, Raipur, Mohali and Vijayawada. Last week, Bharat Biotech said it plans to produce additional 200 million (20 crore) doses of Covaxin at its subsidiary s facility in Gujarat. This will take the overall production volume of the vaccine to about 1 billion (100 crore) doses per annum.